NYSE:NVO

Novo Nordisk A/S Stock Forecast, Price & News

$70.50

+0.53 (+0.76 %)

(As of 01/28/2021 08:02 AM ET)

Add

Compare

Today's Range

$70.50

Now: $70.50▼

$70.50

50-Day Range

$68.72

MA: $70.93▼

$73.80

52-Week Range

$49.24

Now: $70.50▼

$73.92

Volume1 shs

Average Volume1.00 million shs

Market Capitalization$166.01 billion

P/E Ratio26.50

Dividend Yield1.01%

Beta0.46

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

MarketRank^™

Overall MarketRank^™

1.40 out of 5 stars

Medical Sector

539th out of 1,926 stocks

Pharmaceutical Preparations Industry

273rd out of 772 stocks

2.0 Analyst's Opinion

Consensus Rating
Novo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $72.00, Novo Nordisk A/S has a forecasted upside of 2.9% from its current price of $69.97.
Amount of Analyst Coverage
Novo Nordisk A/S has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.1 Community Rank

Outperform Votes
Novo Nordisk A/S has received 347 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Novo Nordisk A/S has received 462 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Novo Nordisk A/S has received 57.11% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote “Outperform” if you believe NVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.7 Dividend Strength

Dividend Yield
Novo Nordisk A/S has a dividend yield of 1.01%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Novo Nordisk A/S does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Novo Nordisk A/S is 30.08%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 25.00% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.07% of the stock of Novo Nordisk A/S is held by insiders.
Percentage Held by Institutions
Only 5.91% of the stock of Novo Nordisk A/S is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Novo Nordisk A/S are expected to grow by 6.47% in the coming year, from $2.78 to $2.96 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novo Nordisk A/S is 26.30, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.66.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novo Nordisk A/S is 26.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 36.55.
Price to Earnings Growth Ratio
Novo Nordisk A/S has a PEG Ratio of 2.21. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Novo Nordisk A/S has a P/B Ratio of 19.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:NVO

Previous Symbol

CUSIPN/A

CIK353278

Webwww.novonordisk.com

Phone45-4444-8888

Employees44,326

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.04

Current Ratio1.04

Quick Ratio0.78

Price-To-Earnings

Trailing P/E Ratio26.50

Forward P/E Ratio25.36

P/E Growth2.21

Sales & Book Value

Annual Sales$18.30 billion

Price / Sales9.07

Cash Flow$2.81 per share

Price / Cash Flow25.10

Book Value$3.65 per share

Price / Book19.32

Profitability

EPS (Most Recent Fiscal Year)$2.46

Net Income$5.84 billion

Net Margins32.65%

Return on Equity71.46%

Return on Assets31.34%

Miscellaneous

Outstanding Shares2,354,800,000

Market Cap$166.01 billion

Next Earnings Date2/3/2021 (Estimated)

OptionableOptionable

$70.50

+0.53 (+0.76 %)

(As of 01/28/2021 08:02 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

How has Novo Nordisk A/S's stock price been impacted by Coronavirus?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVO stock has increased by 20.9% and is now trading at $69.97.
View which stocks have been most impacted by COVID-19.

Is Novo Nordisk A/S a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Novo Nordisk A/S?

Wall Street analysts have given Novo Nordisk A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novo Nordisk A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Novo Nordisk A/S.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its earnings results on Wednesday, November, 4th. The company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.01. The company earned $4.86 billion during the quarter, compared to analyst estimates of $4.75 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 71.46% and a net margin of 32.65%.
View Novo Nordisk A/S's earnings history.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a semi-annual dividend on Friday, August 7th. Investors of record on Monday, August 17th will be paid a dividend of $0.7826 per share on Tuesday, August 25th. This represents a yield of 1.4%. The ex-dividend date is Friday, August 14th.
View Novo Nordisk A/S's dividend history.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.74 per share and currently has a dividend yield of 1.01%. The dividend payout ratio of Novo Nordisk A/S is 30.08%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 25.00% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2020 IntraDay earnings guidance on Friday, October, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20.115-20.69 billion, compared to the consensus revenue estimate of $20.39 billion.

What price target have analysts set for NVO?

9 brokers have issued 12-month target prices for Novo Nordisk A/S's stock. Their forecasts range from $72.00 to $72.00. On average, they anticipate Novo Nordisk A/S's stock price to reach $72.00 in the next year. This suggests a possible upside of 2.9% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S or view Wall Street analyst' top-rated stocks.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 4,090,000 shares, a decrease of 17.9% from the December 15th total of 4,980,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is currently 3.6 days. Approximately 0.2% of the shares of the stock are short sold.
View Novo Nordisk A/S's Short Interest.

Who are some of Novo Nordisk A/S's key competitors?

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche (RHHBY), Novartis (NVS), Abbott Laboratories (ABT), Pfizer (PFE), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX).
View all of NVO's competitors.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:

Mr. Lars Fruergaard JÃ¸rgensen, Pres, CEO & Member of Management Board (Age 55)
Mr. Karsten Munk Knudsen, Exec. VP, CFO & Member of the Management Board (Age 50)
Dr. Mads Krogsgaard Thomsen, Exec. VP, Chief Scientific Officer, Head of R&D and Member of the Management Board (Age 61)
Mr. Henrik Ehlers Wulff, Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board (Age 51)
Ms. Camilla Sylvest, Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board (Age 49)
Ms. Monique Carter, Exec. VP, Head of People & Organisation and Member of Management Board (Age 48)
Mr. Maziar Mike Doustdar, Exec. VP, Head of International Operations & Member of the Management Board (Age 51)
Mr. Douglas J. Langa, Exec. VP, Head of North America Operations & Member of Management Board (Age 55)
Mr. Ludovic Helfgott, Exec. VP, Head of Biopharm & Member of Management Board (Age 47)
Mr. Peter Hugreffe Ankersen, Head of Investor Relations & Corp. VP

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Calamos Advisors LLC (0.01%), QV Investors Inc. (0.01%), Penbrook Management LLC (0.01%), Scout Investments Inc. (0.01%), Janney Montgomery Scott LLC (0.01%) and CWM LLC (0.00%).
View institutional ownership trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, QV Investors Inc., Scout Investments Inc., CWM LLC, Autus Asset Management LLC, Confluence Investment Management LLC, Avantax Advisory Services Inc., and Traynor Capital Management Inc..
View insider buying and selling activity for Novo Nordisk A/S or view top insider-selling stocks.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was acquired by a variety of institutional investors in the last quarter, including Penbrook Management LLC, Chemung Canal Trust Co., Janney Montgomery Scott LLC, Kestra Advisory Services LLC, Keeler Thomas Management LLC, V Wealth Advisors LLC, Stillwater Investment Management LLC, and Palladiem LLC.
View insider buying and selling activity for Novo Nordisk A/S or or view top insider-buying stocks.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $69.97.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $164.77 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis. Novo Nordisk A/S employs 44,326 workers across the globe.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here